# A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors

Source: https://onco.cc/trials/nct07241936/  
OnCo record `nct07241936` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of SYS6010 in advanced solid tumours, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., now recruiting.

## Summary

A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07241936 by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., with 444 participants planned, started 2025-11-13 and due to reach its primary completion in 2027-10-30. Interventions recorded: sirolimus (albumin-bound), DP303c, SYS6043, SYS6002 and SYS6010.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07241936
- Phase: 1/2
- Setting: A Phase Ib/II Clinical Trial on the Safety and Efficacy of Sirolimus (Albumin-bound) Combined With Different ADCs in Patients With Advanced Solid Tumors
- Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Enrolled: 444

## Sources

- ClinicalTrials.gov NCT07241936: https://clinicaltrials.gov/study/NCT07241936

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [SYS6010](https://onco.cc/drugs/sys6010/)
- companies: [CSPC Pharmaceutical Group](https://onco.cc/companies/cspc/)

---
JSON: https://onco.cc/api/v1/entities/nct07241936.json